Corporate ActionJun 30, 2026, 08:26 AM
HCW Biologics Regains Nasdaq Compliance; Announces 1-for-6 Reverse Split
AI Summary
HCW Biologics Inc. announced that it has regained compliance with Nasdaq's Bid Price Rule, Listing Rule 5550(a)(2), as determined by the Nasdaq Hearings Panel on June 29, 2026. The company will be under a mandatory monitoring period until June 17, 2027. To maintain long-term compliance, HCW Biologics will implement a one-for-six reverse stock split on June 30, 2026.
Key Highlights
- HCW Biologics regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule.
- Compliance was confirmed by the Nasdaq Hearings Panel on June 29, 2026.
- The company is subject to a mandatory monitoring period through June 17, 2027.
- A one-for-six reverse stock split will be effected on June 30, 2026.
- The reverse stock split aims to ensure long-term compliance with the Bid Price Rule.
Price Impact
More from HCWB